Decayed Hepatic Phosphatidylinositol-3,4,5-Triphosphate (PIP3) Levels and Impaired Glucose Homeostasis in Type 1 and Type 2 Diabetic Rats

Prasenjit Manna      Sushil K. Jain

Department of Pediatrics, Louisiana State University Health Sciences Center, Shreveport, LA

Key Words
PIP3 • PIP2 • Type 1 and Type 2 Diabetic Rats • Livers • Glucose metabolism

Abstract

Background/Aims: Phosphatidylinositol-3,4,5-triphosphate (PIP3) and phosphatidylinositol-4,5-biphosphate (PIP2) are two well-known lipid second messengers. Polyphosphoinositides have been implicated in the regulation of the signal transduction pathways involved in glucose metabolism using cell culture studies. However, there are no in vivo studies in the literature investigating the status of PIP3 and PIP2 in any of the tissues of diabetic animals. The liver plays an important role in the regulation of whole body glucose homeostasis. This study investigated whether hepatic PIP3 and/or PIP2 levels are altered in diabetes.

Methods: Experiments were performed in streptozotocin-treated type 1 (T1D) and ZDF type 2 (T2D) diabetic rats. Blood glucose was determined utilizing glucose oxidase, glycosylated hemoglobin (GHb) using Glyco-Tek Affinity columns, and hepatic PIP3 and PIP2 concentrations by sandwich ELISA, and Akt phosphorylation and GLUT2 protein abundance by Western blotting. Results: Blood glucose and GHb were higher in T1D and T2D rats compared to controls. As compared to control animals, in livers from T1D and T2D rats PIP3 levels were reduced, AKT phosphorylation downregulated, and GLUT2 protein expression increased. PIP2 levels were unchanged. Conclusion: PIP3 is decreased, AKT phosphorylation downregulated, GLUT2 protein expression increased and glucose homeostasis altered in livers of type 1 and type 2 diabetic rats.

Introduction

Polyphosphoinositides (PIs) play an essential role in diverse cellular functions depending upon the phosphorylation status of their inositol group [1]. PIP3 (phosphatidylinositol-...
3,4,5-triphosphate) and PIP2 (phosphatidylinositol-4,5-biphosphate) are two well known signaling molecules [2]. PIP3 controls a complex intracellular signaling network that regulates many cellular processes, such as cell growth, proliferation, and survival [3]. PIP3 target proteins are located in the cytosol of unstimulated cells and are activated via binding of the PH (pleckstrin homology) domain with PIP3 [4]. This lipid molecule regulates a variety of PH domain-containing proteins, such as serine-threonine kinase AKT and PDK1, GRP1, a GDP/GTP exchange factor of ADP ribosylating factor 6, and protein tyrosine kinases of the Bruton's tyrosine kinase (Btk) and Tec families [5, 6]. This diversity in PIP3 signaling makes this molecule an important lipid second messenger downstream from growth factor and oncogene signaling cascades. On the other hand, PIP2 regulates a variety of diverse cellular activities, including modulation of the actin cytoskeleton, endocytosis, exocytosis, and ion channel activity [7].

Insulin stimulated glucose uptake and metabolism is one of the fundamental mechanisms responsible for the maintenance of glucose homeostasis in the body. Impaired insulin action or insulin resistance leads to type 2 diabetes (T2D). PI3K (phosphoinositide-3-kinase) and PTEN (phosphatase and tensin homologue deleted on chromosome 10) play central roles in the insulin signaling cascade and glucose metabolism [8]. The activation of Class I PI3K causes phosphorylation of PIP2 at position 3 of its inositol head group, leading to the formation of PIP3, but PTEN activation causes the degradation of PIP3 [1]. This means that the cellular PIP3 concentration is regulated by the PI3K/PTEN equilibrium. Studies in the literature have shown that inhibition of PTEN expression using PTEN antisense oligonucleotides normalized blood glucose levels in ob/ob (obese) mice [9] and that overexpression of PTEN resulted in inhibition of PIP3 production and glucose uptake [10]. Similarly, various studies using knockout mice and cell models of PTEN and PI3K have documented that inhibition of PTEN, and activation of PI3K and AKT (serine/threonine protein kinase) signaling molecules, are crucial in insulin signaling pathways and the maintenance of whole body glucose metabolism [11]. These findings suggest that PIP3 can play a role in the insulin signaling pathway [1, 3]. Our previous study in adipocyte (3T3L1) cell model indicates that high glucose exposure caused a decrease in cellular PIP3, downregulation of AKT phosphorylation and GLUT4 (glucose transporter 4) expression, and reduction of glucose utilization [12]. Exogenous PIP3 supplementation however could upregulate the AKT phosphorylation and GLUT4 expression, and glucose utilization in high glucose treated adipocytes. Using 3T3L1 adipocytes, Funaki et al. [13] also reported that in the presence of a cell permeable phosphoinositide-binding peptide (PBP10), PIP2 functions as a second messenger in GLUT4 activation and glucose uptake, possibly through regulation of F-actin remodeling. However, there are no in vivo studies in the literature investigating the status of PIP3 and PIP2 in any of the tissues of diabetic animals. The liver plays a crucial role in the maintenance of body glucose homeostasis, and hepatic insulin resistance is a major risk factor in the development of diabetes and its associated complications. Using both type 1 (T1D) and type 2 diabetic (T2D) rats, this study investigated the status of PIP3 and PIP2 in the liver tissues of diabetic animals and their effect on hepatic glucose metabolism. Livers from both T1D and T2D rats showed a reduction in hepatic PIP3 levels, downregulation of AKT phosphorylation, and an increase in GLUT2 (glucose transporter 2) protein expression; however, PIP2 levels were unchanged. This study demonstrates for the first time a decrease in hepatic levels of PIP3 but not those of PIP2, which may have a role in the impaired glucose homeostasis in type 1 and type 2 diabetic rats.

Materials and Methods

Materials

GLUT2 antibody was purchased from Millipore (Billerica, MA). AKT and phospho AKT (serine 473) were purchased from Cell Signaling Technology (Beverly, MA). All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) unless otherwise mentioned.
Animal studies

All procedures used in our study were in accordance with the ethical standards of the institution, and prior approval was obtained from the institutional Animal Welfare Committee.

Studies with type 1 diabetic animals

Male Sprague Dawley (SD) rats were purchased at 5 weeks of age (200–220 g) from Charles River (Wilmington, MA) and allowed 2 days for environmental and trainer handling acclimation. The rats were fasted overnight and then injected with streptozotocin (STZ) intraperitoneally at a dose of 65 mg/kg body weight in citrate buffer (pH 4.5). Control rats were injected with citrate buffer alone to serve as a normal control group (Cont) for type 1 diabetes (T1D). The rats were tested for hyperglycemia (blood glucose >300 mg/dL) by measuring their blood glucose concentrations at 3 and 7 days after the STZ injections. The rats were maintained under standard housing conditions at 22 ± 2°C with 12/12-h light/dark cycles and fed with a standard 8640 lab chow diet (Harlan, Indianapolis, IN). At the age of 14 weeks, the rats were fasted overnight and then euthanized by exposure to isoflurane (Webster Veterinary Supply Inc., Devens, MA) on the next day for analysis.

Studies with type 2 diabetic animals

Male Zucker Diabetic Fatty (ZDF) rats were purchased at 5 weeks of age (200–220 g) from Charles River (Wilmington, MA) and allowed 2 days for environmental and trainer handling acclimation. Rats were fasted overnight and then weighed. The rats were maintained under standard housing conditions at 22 ± 2°C with 12/12-h light/dark cycles and fed with a high-calorie Purina 5008 lab chow diet (Charles River). The rats were tested for hyperglycemia by measuring their blood glucose concentrations. At 14 weeks of age the ZDF rats became diabetic (blood glucose >300 mg/dL) (T2D). For age matched controls, male Sprague Dawley (SD) rats were also purchased (Charles River) at the age of 5 wks, fed a normal diet, and maintained under similar conditions until they reached 14 weeks of age. In addition, normoglycemic prediabetic ZDF rats (6 wks) were used as baseline (BL) controls. At the end of the experiment, diabetic ZDF rats (T2D), non-diabetic SD rats (age-matched controls) and baseline ZDF rats (BL) were fasted overnight and euthanized by exposure to isoflurane (Webster Veterinary Supply Inc., Devens, MA) on the next day for analysis.

For the assessment of blood glucose levels, blood was obtained via tail incision and measured using an Advantage Accu-Chek glucometer (Boehringer Mannheim Corp., Indianapolis, IN). Blood was collected via heart puncture with a 19½-gauge needle into EDTA Vacutainer tubes. Plasma was isolated after centrifuging the blood in a 4°C centrifuge at 1500 rpm for 10 min.

Measurement of blood glucose, glycosylated hemoglobin (GHb), and liver function tests

Blood glucose levels were determined by measuring glucose oxidase using an Accu-Chek Advantage glucometer (Boehringer Mannheim). GHb was determined using Glyco-Tek Affinity column kits and reagents (Cat. No. 5351) purchased from Helena Laboratories (Beaumont, TX, USA). A portion of blood from rats in each group was sent to the clinical laboratory of LSUHSC-Shreveport (located in the same building) for clinical tests to determine liver function.

Preparation of liver tissue homogenates

Liver tissues excised from the experimental rats were immediately perfused with cold saline to remove left over blood, immediately frozen using liquid nitrogen, then ground well into powders and stored at -70°C until further use. The frozen liver tissue (~150 mg) was washed by resuspending then in 1 mL PBS containing protease inhibitors, mildly vortexed, and centrifuged at 15,000 rpm at 4°C for 10 min. The supernatants were discarded and the cell pellets were washed once more as described above and then resuspended in 500 µL radioimmuno precipitation assay (RIPA) buffer (50 mM Tris pH 8, 150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS) supplemented with protease and phosphatase inhibitors (1 mM PMSF, 5 µg/mL leupeptin, 2 µg/mL aprotinin, 1 mM EDTA, 10 mM NaF, and 1 mM NaVO4), homogenized using a Dounce homogenizer, and subjected to mild sonication. The tubes were centrifuged at 15,000 rpm (4°C, 30 min) and the supernatants (extracts) were collected. The collected extracts were subjected to centrifugation once more as described above and cell debris was removed. The protein content of the extracts was estimated using the BCA protein assay kit (Pierce/Thermo Scientific, Rockford, IL).
**Measurement of PIP3 and PIP2 levels**

PIP3 and PIP2 concentrations in the liver tissue were measured by the sandwich ELISA method using commercially available kits from Echelon Biosciences, Inc. (Salt Lake City, UT). Before estimating the cellular PIP3 and PIP2 concentration, total phosphoinositides were extracted from the liver tissue homogenate following the method as described by Grey et al. [14] as well as in the kits. The frozen liver tissue (~150 mg) was homogenized in 50 mM potassium phosphate buffer (pH 6.9) containing 1 mM EDTA and 1:100 (v/v) protease inhibitor cocktail (Calbiochem) followed by centrifugation at 15,000 X g for 30 min at 4°C. The resulting supernatant was used to extract the phosphoinositides. Before extraction, proteins and the lipids present in the homogenates were precipitated by adding 0.5 mL ice cold 0.5 M TCA. After standing on ice for 5 min the precipitate was pelleted by centrifugation at 1500 X g for 5 min at 4°C. The pellet was then washed two times with 1 mL of 5% TCA 1 mM EDTA. Neutral lipids were extracted first from the pellet with methanol:chloroform (2:1) by vortexing three to four times over a period of 10 min at room temperature followed by centrifugation at 1500 X g for 5 min at 4°C. This extraction was repeated and the supernatants were discarded. The acidic lipids were then extracted with methanol:chloroform:12M HCl (80:40:1) by vortexing occasionally over a 15 min period at room temperature followed by centrifugation at 1500 X g for 5 min at 4°C. This extraction was repeated and the supernatant was collected. A phase split was then carried out by the addition of 750 µL chloroform and 1.35 mL 0.1 M HCl followed by centrifugation to separate the organic and aqueous phases at 1500 X g for 5 min at 4°C. The organic phase was collected into a clean tube and dried under a stream of N₂. The dried lipids were then resuspended in 60 µL of the assay buffer (PBS-T 3% Protein Stabilizer) provided in the manufacturer kit, vortexed and sonicated briefly in an ice water bath to dissolve the phosphoinositides. The mass of phosphoinositides were estimated using the respective ELISA kits (PIP3 Mass ELISA kit # K-2500s and PIP2 Mass ELISA kit # K-4500). Appropriate controls and standards (specified by each manufacturer’s kit) were used every time.

**Immunoblotting**

All samples contained approximately the same amount of protein (~20–40 µg) and were run as 10% SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked at room temperature for 2 h in blocking buffer containing 1% BSA to prevent non-specific binding and then incubated with: anti-AKT (AKT2) (1:1000 dilution), anti-GLUT2 (1:1000), and anti-phosphorylated AKT (serine 473) (1:500) primary antibodies at 4°C overnight. The membranes were washed in TBS-T (50 mmol/L Tris-HCl, pH 7.6, 150 mmol/L NaCl, 0.1% Tween 20) for 30 min and incubated with the appropriate HRP conjugated secondary antibody (1:5000 dilution) for 2 h at room temperature and developed using the ultrasensitive ECL substrate (Millipore, MA). The intensity of each immunoblotting band was measured using the histogram tool of Adobe Photoshop CS5.

**Statistical analysis**

Data from cell culture studies were analyzed statistically using one way analysis of variance (ANOVA) with Sigma Stat statistical software (Jandel Scientific, San Rafael, CA). When data passed a normality test, all groups were compared using the Student–Newman–Keuls method. A difference was considered significant at the p < 0.05 level.

**Results**

Tables 1 and 2 show the levels of blood glucose, glycated hemoglobin (GHb), and the status of the serum enzymes related to hepatic dysfunction, ALT (alanine transaminase) and AP (alkaline phosphatase), in the blood samples of all the experimental animals. Results (Table 1) showed that STZ-treated T1D rats have higher levels of blood glucose and GHb compared to those seen in controls (Cont). In addition, T1D rats also have higher levels of ALT and AP compared to those of controls (Cont). Similarly, T2D rats also exhibit higher levels of blood glucose, GHb, and ALT and AP compared to those of age matched (14 wk) control SD rats and normoglycemic young (6 wk) ZDF rats (BL) (Table 2). We also observed that the body weights of T1D and T2D rats were reduced compared to those of age matched control rats.
Figures 1 and 2 show the levels of PIP3, PIP2, and the expression of different signaling molecules (AKT and GLUT2) involved in glucose metabolism pathways in the liver tissues of normal and diabetic rats. The results in Figure 1 show that livers from T1D rats have lower levels of PIP3 (1C), along with downregulation of phospho AKT (1A) and upregulation of GLUT2 expression (1B), compared to that of controls. Livers from T2D rats also show lower PIP3 levels (2C), phosphorylation of AKT (2A), and an increase in GLUT2 (2B) protein expression compared to those seen in both age matched control SD rats and normoglycemic young ZDF rats (BL). However, PIP2 levels were unchanged in liver tissue of both types of rats compared to those seen in controls (1D and 2D). In the human body, the liver plays an important role in the regulation of glucose homeostasis, and an increased hepatic glucose output contributes to fasting hyperglycemia in diabetes [15]. The results from our *in vivo* studies demonstrate a reduction in hepatic PIP3 as well as impaired glucose metabolism in diabetic rats.

Table 1. Age, body weight, blood glucose, glycosylated hemoglobin (GHb), and liver function tests (ALT and AP) of the experimental rats.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cont</th>
<th>T1D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (wk)</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>Body weight (gm)</td>
<td>376±6*</td>
<td>149±9#</td>
</tr>
<tr>
<td>Blood glucose (mg/dL)</td>
<td>143±6.5*</td>
<td>446±24#</td>
</tr>
<tr>
<td>Blood GHb (%)</td>
<td>7.68±0.17*</td>
<td>16.98±0.38#</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>63.67±3.6*</td>
<td>178±36.2#</td>
</tr>
<tr>
<td>AP (U/L)</td>
<td>14.8±2.75*</td>
<td>38.5±5.23#</td>
</tr>
</tbody>
</table>

Each value represents the mean±SE (n=6). ALT, alanine aminotransferase; AP, alkaline phosphatase. Cont: SD rats at the age of 14 wks and T1D: streptozotocin treated type 1 diabetic SD rats at the age of 14 wks. Differences between * vs # are considered significant (p < 0.05).

Table 2. Age, body weight, blood glucose, glycosylated hemoglobin (GHb), and liver function tests (ALT and AP) of the experimental rats.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Cont</th>
<th>T2D</th>
<th>BL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (wk)</td>
<td>14</td>
<td>14</td>
<td>6</td>
</tr>
<tr>
<td>Body weight (gm)</td>
<td>439±18*</td>
<td>375±7#</td>
<td>146±5**</td>
</tr>
<tr>
<td>Blood glucose (mg/dL)</td>
<td>115±16*</td>
<td>486±36#</td>
<td>89±3.32*</td>
</tr>
<tr>
<td>Blood GHb (%)</td>
<td>5.39±0.14*</td>
<td>14.23±0.51#</td>
<td>5.11±0.19*</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>51.16±6.94*</td>
<td>128±12.8#</td>
<td>65±3.53*</td>
</tr>
<tr>
<td>AP (U/L)</td>
<td>15.33±3.01*</td>
<td>49.5±7.67#</td>
<td>9.2±1.36*</td>
</tr>
</tbody>
</table>

Each value represents the mean±SE (n=6). ALT, alanine aminotransferase; AP, alkaline phosphatase. Cont: SD rats at the age of 14 wks (age matched control); T2D: type 2 diabetic ZDF rats at the age of 14 wks; and BL: normoglycemic young ZDF rats at the age of 6 wks. Differences between * vs #, **vs # and * vs** are considered significant (p < 0.05).
The liver plays an important role in the regulation of body glucose homeostasis. Hepatic insulin resistance is one of the major risk factors in the pathogenesis of diabetes mellitus [15]. Polyphosphoinositides (PIs) play an essential role in diverse cellular functions depending upon the phosphorylation status of their inositol group [1]. Present study demonstrates for the first time that livers from T1D and T2D rats have lower PIP3 levels, downregulation of phospho AKT, and an increase in GLUT2 expression compared to those seen in controls, but that PIP2 levels were unchanged.

In our bodies glucose homeostasis is a tightly regulated phenomenon, which involves glucose uptake by peripheral tissues and glucose storage by, or production from the liver. Under normal conditions, the liver can store or release glucose as needed. In the postprandial state, glucose is taken up by the liver and is incorporated into glycogen and fatty acids or oxidized into CO2. However, in the fasting state, the liver releases glucose into the blood stream via glycogenolysis and gluconeogenesis. Thus glucose transport across the liver...
plasma membrane is a bidirectional process. In liver, GLUT2 is the main isoform of glucose transporters and due to its high $K_m$ value, it allows rapid equilibration of the intracellular with the extracellular glucose level within the physiological range of plasma glucose concentrations [16, 17]. Studies in the literature suggest that under diabetic pathophysiology, hepatic glucose homeostasis is markedly disturbed due to increased hepatic insulin resistance [15, 18]. It has been reported that hepatic insulin resistance is associated with hepatic steatosis, causing impaired glycogen synthesis and increased gluconeogenesis, which may cause altered glucose homeostasis in diabetic liver tissues [15, 19, 20]. Recent studies report that increased hepatic fat accumulation upregulates the concentration of hepatic diacylglycerol (DAG) [18]. The accumulation of DAG causes the activation of protein kinase Cε (PKCε), which subsequently inhibits insulin receptor kinase. This leads to decreased insulin stimulated tyrosine phosphorylation of insulin receptor substrate-1 and -2 (IRS-1, IRS2), resulting in reduced activation of PI3K and AKT. Reduction in AKT phosphorylation decreases the glycogen synthase (GS) mediated glycogen synthesis and increases gluconeogenesis, which in turn leads to glucose release through GLUT2 [18]. Various studies in the literature report that the concentrations of both GLUT2 protein and mRNA were increased 1.6- to 2-fold in diabetic rat livers [21, 22]. PIP3 plays an important role in the insulin signaling pathway [3]. Cellular PIP3 concentration is regulated by PI3K/PTEN equilibrium, and upon formation, PIP3 causes the activation of AKT, leading to increased glucose metabolism. However, there are no previous reports in the literature concerning whether hepatic PIP3 levels are altered in diabetes.

Results from this in vivo study document that, while livers from T1D and T2D rats show a reduction in hepatic PIP3 levels, phosphorylation of AKT, and an increase in GLUT2 protein expression compared to those of controls, the PIP2 levels remain unchanged. This suggests that a decrease in hepatic levels of PIP3 but not those of PIP2, may be linked to downregulation of AKT phosphorylation. This can contribute to impaired glycogen synthesis and increased gluconeogenesis, and is associated with increased hepatic glucose output as manifested by upregulation of GLUT2 protein expression. This study demonstrates for the first time that a decrease in hepatic PIP3 levels may have a role in altered glucose homeostasis in diabetes.

Diabetes is associated with hyperglycemia and increased oxidative stress, which can upregulate PTEN and downregulate PI3K, leading to a decrease in cellular PIP3. This study demonstrates for the first time a decrease in hepatic levels of PIP3 but not those of PIP2, which may have a role in the downregulation of AKT/ GLUT2 protein expression and glucose metabolism in diabetes. Further studies are needed to investigate the direct effect of PIP3/IP2 in hepatocytes to understand the causal relationship of PIP3/IP2 with glucose metabolism. Future studies on the status of PIP3 in other tissues are needed to further evaluate the role of PIP3 as a biomarker for insulin resistance and impaired glucose homeostasis in diabetes. This could lead in turn to new therapeutics that target improvement of PIP3 status in diabetes.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Acknowledgements

The authors are supported by grants from NIDDK and the Office of Dietary Supplements of the National Institutes of Health RO1 DK072433 and the Malcolm Feist Endowed Chair in Diabetes. This study is also funded by a fellowship from the Malcolm Feist Cardiovascular Research Endowment, LSU health Sciences Center, Shreveport. The authors thank Ms Georgia Morgan for excellent editing of this manuscript.
Manna/Jain: PIP3, PIP2 and Hepatic Glucose Homeostasis

References


